Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 51 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Keyword is Fatty Liver  [Clear All Filters]
Journal Article
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Polyzos, S. A., Kountouras J., Papatheodorou A., Katsiki E., Patsiaoura K., Zafeiriadou E., et al. (2013).  Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.. Ann Hepatol. 12(5), 749-57.
Polyzos, S. A., Kountouras J., Zavos C., & Stergiopoulos C. (2010).  Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: the two sides of the same coin.. Med Hypotheses. 74(6), 1089-90.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Cardiovascular benefits of bariatric surgery in morbidly obese patients.. Obes Rev. 12(7), 515-24.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Fotiadu, A., Gagalis A., Akriviadis E., Kotoula V., Sinakos E., Karkavelas G., et al. (2010).  Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease.. Pathol Int. 60(2), 87-92.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Levelt, E., Pavlides M., Banerjee R., Mahmod M., Kelly C., Sellwood J., et al. (2016).  Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes.. J Am Coll Cardiol. 68(1), 53-63.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.
Polyzos, S. A., Kountouras J., Zafeiriadou E., Patsiaoura K., Katsiki E., Deretzi G., et al. (2011).  Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.. J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
Polyzos, S. A., Kountouras J., Deretzi G., Zavos C., & Mantzoros C. S. (2012).  The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.. Curr Mol Med. 12(1), 68-82.
Polyzos, S. A., Kountouras J., Papatheodorou A., Patsiaoura K., Katsiki E., Zafeiriadou E., et al. (2013).  Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.. Metabolism. 62(1), 121-6.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Kountouras, J., Polyzos S. A., Zavos C., Deretzi G., Kountouras C., Vardaka E., et al. (2014).  Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors.. Hepatology. 60(4), 1450-1.
Hall, A. R., Dhillon A. P., Green A. C., Ferrell L., Crawford J. M., Alves V., et al. (2013).  Hepatic steatosis estimated microscopically versus digital image analysis.. Liver Int. 33(6), 926-35.
Polyzos, S. A., & Kountouras J. (2016).  Homocysteine in nonalcoholic steatohepatitis: A reply.. Eur J Intern Med. 35, e40-e41.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 9(6), 698-705.
Athyros, V. G., Tziomalos K., Katsiki N., Gossios T. D., Giouleme O., Anagnostis P., et al. (2013).  The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study.. Curr Vasc Pharmacol. 11(5), 779-84.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Kountouras, J., Polyzos S. A., Katsinelos P., Doulberis M., Zavos C., Kazakos E., et al. (2017).  Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.. Aliment Pharmacol Ther. 46(6), 637-638.
Kountouras, J., Polyzos S. A., Kapetanakis N., Katsinelos P., Nikolopoulos P., Stogianni A., et al. (2017).  Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.. Aliment Pharmacol Ther. 45(4), 576-577.
Savvidou, S., Hytiroglou P., Orfanou-Koumerkeridou H., Panderis A., Frantzoulis P., & Goulis J. (2009).  Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.. J Clin Gastroenterol. 43(8), 765-72.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές